Key Highlights

  • Actinogen received an R&D tax incentive rebate of $10,838,793, including interest, for the 2026 financial year.
  • A $4.3 million loan from Endpoints Capital, advanced against the rebate, was repaid with interest from the gross amount.
  • Net proceeds of $5,993,390 lift the pro-forma cash position to $21.9 million, with no debt.
  • Topline results from the XanaMIA phase 2b/3 Alzheimer's trial are expected in mid-November 2026.

Actinogen Medical (ASX:ACW) announced on 26 October 2026 that it received a research and development tax incentive (RDTI) rebate of $10,838,793, including interest, from the Australian Tax Office for the 2026 financial year. The payment arrives as the biotechnology company approaches topline results from its phase 2b/3 trial of Xanamem in Alzheimer's disease, and it changes the company's cash and debt position.

Rebate Received and Loan Repaid

The RDTI is an Australian federal government program that pays cash rebates for eligible research and development expenditure through a refundable tax offset. Actinogen noted that it forms an important part of the company's ongoing sources of funds. The gross rebate included interest and totalled $10,838,793.

The company had borrowed $4.3 million from Endpoints Capital as an advance against its FY26 rebate. That loan, plus interest, was repaid from the gross amount, which left net proceeds of $5,993,390. By implication, loan principal and interest accounted for roughly $4.8 million of the gross payment. Combined with the previously announced cash balance of approximately $15.9 million at 30 September 2026, the net proceeds give a pro-forma quarter-end cash position of $21.9 million, and the company confirmed it carries no debt.

The Trial Behind the Spending

Much of the research spending that qualifies for the rebate relates to Xanamem, a once-daily oral therapy designed to reduce cortisol in the brain by inhibiting the enzyme 11β-HSD1. The XanaMIA phase 2b/3 trial is a double-blind, placebo-controlled study of 36 weeks in 247 patients with mild to moderate Alzheimer's disease and progressive disease confirmed by an elevated blood level of the pTau181 biomarker. Participants receive Xanamem 10 mg or placebo, and the primary endpoint is the Clinical Dementia Rating scale Sum of Boxes (CDR-SB).

The trial runs in Australia and the United States, is closed to recruitment, and has passed an independent Data Monitoring Committee safety and efficacy futility review. The company expects topline final results in mid-November 2026. A related open-label extension, XanaMIA-OLE, began in March 2026 and offers up to 25 months of active treatment to former and current participants. Separately, the XanaCIDD phase 2a trial in 167 patients with treatment-resistant depression reported results in August 2024, showing benefits on depression symptom scales while cognition improved to a similar extent in both the Xanamem and placebo groups. The company reports that Xanamem has been studied in more than 500 volunteers and patients across eight clinical trials, and that a human PET imaging study showed high levels of target engagement in the brain at doses as low as 5 mg daily. Xanamem remains an investigational product and is not approved for use outside clinical trials by the FDA or any global regulatory authority.

Why This Could Matter

The announcement adjusts the balance sheet ahead of a scheduled trial readout. Before the rebate, the company carried a $4.3 million advance; after it, cash is higher and the loan is gone. The payment is tied to past research spending, so it is a reimbursement mechanism rather than new funding from investors, and the amount depends on eligible expenditure and government processes each year.

The size of the cash position matters because late-stage clinical programs carry ongoing costs, and the outcome of the mid-November results has not been disclosed. The company's statement is limited to the cash figure and the confirmation of no debt, and it makes no comment on the trial outcome.

The Bottom Line

Actinogen's rebate has cleared a $4.3 million loan and lifted pro-forma cash to $21.9 million ahead of the mid-November trial readout. The trial results themselves have not been reported, and the announcement makes no statement about them.